Management of Pancreatic Exocrine Insufficiency in Chronic Pancreatitis

Indications for Starting Creon

The American Gastroenterological Association recommends initiating Creon in patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI), even in mild to moderate disease, as fat malabsorption can occur despite minimal pancreatic damage 1, 2
Patients presenting with steatorrhea, unexplained weight loss, gastrointestinal symptoms, diarrhea or loose watery stools, and increased flatulence and abdominal distention should be started on Creon 2, 3, 4
The absence of steatorrhea does not rule out the need for treatment, as PEI may exist without obvious clinical symptoms 2

Fecal elastase <100 μg/g of stool provides definitive evidence of PEI, while levels between 100-200 μg/g are indeterminate but warrant treatment trial if clinical suspicion exists 3
Evidence of fat-soluble vitamin deficiencies and biochemical signs of malnutrition also indicate the need for Creon therapy 5

The American College of Gastroenterology recommends starting with at least 40,000 USP units of lipase with each main meal in adults, and 20,000 USP units with snacks 7, 3
Dosage should be adjusted based on meal size and fat content, persistence of steatorrhea, ongoing gastrointestinal symptoms, and weight gain or loss 7

Acid suppression with proton pump inhibitors or H2-receptor antagonists may be necessary when PERT alone is insufficient in relieving symptoms 6, 8
Nutritional management with fat-soluble vitamin supplementation, low-moderate fat diet, and high protein intake should be implemented alongside Creon therapy 7, 3, 8

Treatment response should be assessed through reduction in steatorrhea and gastrointestinal symptoms, weight gain, increased muscle mass and function, improvement in fat-soluble vitamin levels, body mass index changes, and quality of life measures 7, 3
Baseline dual-energy x-ray absorptiometry (DEXA) scan should be obtained and repeated every 1-2 years to monitor for osteoporosis 3